Study to Find Maintenance Dose for Periodic Administration of ASP3550
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.
Condition or disease
ASP3550 is administered periodically to patients with prostate cancer. The primary efficacy variable is the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically proven prostate cancer (adenocarcinoma) of all stages
A patient in whom endocrine treatment is indicated. Patients with rising serum PSA after having prostatectomy or radiotherapy performed with curative intention
Serum testosterone level above 2.2 ng/mL
An ECOG (Eastern Co-operative Oncology Group) P.S. (Performance Status) score of 0 to 2
Serum PSA level above 2 ng/mL
Previous or present endocrine treatment for prostate cancer. However, patients who have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6 months and in whom prostatectomy or radiotherapy was terminated at least 6 months
Treated with a 5α-reductase inhibitor
A candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months
Concurrent or a history of severe liver disease
Abnormal ECG such as long QTc
A patient receiving ASP3550 in past times
Administered drug in another clinical study or a post-market clinical study in the 28 days prior to the study